Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

HLS Therapeutics Inc. (T:HLS)

Business Focus: Retail - Drugs without Grocery

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for HLS within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Nov 19, 2020 05:30 ET
HLS Therapeutics Establishes Automatic Share Purchase Plan
TORONTO, Nov. 19, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that in connection with its previously announced normal course issuer bid ("NCIB") to purchase up to an aggregate of 1,587,193 of its issued and outstanding common shares (each, a "Common Share"), it has entered into an automatic share purchase plan ("ASPP") with a designated broker, Haywood Securities Inc. The ASPP allows for the purchase of Common Shares under the NCIB at any time, including when
Read full article
Nov 17, 2020 05:30 ET
HLS Therapeutics Announces Health Canada Approval of PERSERIS® for the Treatment of Schizophrenia
first once-monthly risperidone long-acting injectable used in the treatment of schizophrenia once-monthly dosing may help improve treatment compliance PERSERIS is a first-line treatment option for schizophrenia and is commercially complementary to Clozaril®, which is for treatment resistant schizophrenia TORONTO, Nov. 17, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that Health Canada has approved the use of PERSERIS® (risperidone for extended-release inject
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
0.66
--
--
Price to Sales - TTM
8.43
4.34
3.09
Price to Book - most recent quarter
2.67
1.46
3.28
Price to Cash Flow per share - TTM
39.08
39.08
14.06
Price to Free Cash Flow per share - TTM
--
--
18.06
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Nov 15, 202019,158-10,748
Oct 31, 202029,9066,208
Oct 15, 202023,6984,543
See Short Report

Business Summary

Sector:  Consumer Non-Cyclicals Industry:  Drug Retailers

HLS Therapeutics Inc is a Canada-based company specialized in the pharmaceutical industry. The Company acquires and distributes commercial stage and branded pharmaceutical drugs for the North American markets. The Company focuses mainly on treatment products for the central nervous system and cardiovascular specialties in Canada. Its product pipeline includes clozaril, for the treatment of schizophrenia disorders; absorica, for treatment of skin disease, such as acne; vascepa, for the treatment of hypertriglyceridemia, and trinomial for cardiovascular risk reduction. Apart from its operation in a number of regions in Canada, such as Toronto, Ontario, and Montreal, the Company also operates in the United States.

See business summary

 

Twitter

Search (past week) for $HLS.CA

  • No tweets found